LUCID-MS: Patented new chemical entity (NCE)
Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions.
Lucid-MS has shown excellent results in several animal models.
LUCID-MS: Disease Modifying Enabling Remyelination
A sampling of the novel qualities of Lucid-MS include:
- Excellent efficacy in various preclinical animal models
- Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation
- Does not suppress immune system (non-immunomodulatory)
- Potential oral administration with easy dosing regimen
Quantum BioPharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS.
Today there is no cure for Multiple Sclerosis.
Quantum BioPharma ("QNTM") is trying to change this for millions of people.
Grab Sources And More: QNTM Website. QNTM Presentation.
-----
(Nasdaq: QNTM): 5 Potential Breakout Catalysts To Consider
#1. QNTM Potential Catalyst - A Minuscule Float Could Provide Strong Potential For Explosive Volatility.
According to the Yahoo Finance website, QNTM has a very small float.
In fact, the website reports this profile to have approximately 1.6Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides more positive company news in the first half of 2025, could it provide a near term spark?
-----
#2. QNTM Potential Catalyst - An Analyst Target Suggests (Nasdaq: QNTM) May Be Undervalued From Current Levels.
In August of 2024, BJ Cook, an analyst with Singular Research, updated a price target for QNTM to $12.80.
From Friday's closing valuation, that target provides QNTM with a potential upside of over 45%!
And don't forget, QNTM has already shown the ability to run down that $12.80 price target on the way to a 2025 high of $18.00!
Here are a few highlights from the report:
- The successful launch of unbuzzdTM on Amazon, marks a significant milestone for the firm.
- Furthermore, ethics approval in Australia for Phase-1 multiple ascending dose study for Lucid-MS signifies a crucial step in the progress towards development of a novel treatment for multiple sclerosis.
- We reiterate our Buy-Venture rating and adjust our target price to $12.80 per share.
-----
#3. QNTM Potential Catalyst - Positive Effects Of unbuzzd™ Rapidly Apparent, Occurring Within 30 Min. After Consumption.
Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover
TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolism.
Results of data analysis show definitively that unbuzzd™ accelerated the rate at which Blood Alcohol Concentration ("BAC") was reduced in study subjects, while simultaneously reducing the symptoms of intoxication and hangover. All these results were statistically significant compared to placebo. Study participants were both male and female and between the ages of 21 and 43, with weights ranging from 119 to 232 pounds.
The positive effects of unbuzzd™ were rapidly apparent, occurring within 30 minutes after consumption of the dissolved powder. unbuzzd™ was well-tolerated and safe, with no reported product-related adverse effects.
...
"We are thrilled to see such significant and meaningful outcomes in this clinical study. This study confirms the exceptional overall performance of unbuzzd™ to help reduce the acute effects of alcohol intoxication," said Dr. Andrzej Chruscinski, Vice President of Clinical and Scientific Affairs at Quantum Biopharma. "We are also pleased to see that there were no product-related side effects or safety concerns in this clinical study."
Zeeshan Saeed, CEO of Quantum BioPharma added, "This clinical trial shows that unbuzzd™ is an important addition to the safe and responsible consumption of alcohol. Consumers now have the benefit of knowing that unbuzzd™ can reduce alcohol intoxication, speed the reduction of blood alcohol concentration, restore mental alertness and well-being, and help them avoid the worst symptoms of a hangover."
...
Read the full article here.
-----
#4. QNTM Potential Catalyst - Another Milestone Reached As Company Shares Completion Of Key Phase 1 Trial.
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
Safety Review Committee Found No Safety Concerns Following Milestone Trial
TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), today announced that it has completed its trial entitled "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants." A final safety review committee ("SRC") meeting was held after completion of the trial. The SRC found that Lucid-21-302 "(Lucid-MS") was well-tolerated with no safety concerns and no serious adverse events were reported during the trial.
...
"Our clinical development team is thrilled that this Phase 1 trial is now complete, and that Lucid-MS was deemed safe and well-tolerated in healthy participants," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma. "This marks an important milestone and allows for the next steps in the clinical development of Lucid-MS."
Zeeshan Saeed, CEO of Quantum BioPharma added, "We are excited about the potential of Lucid-MS to protect myelin in MS patients as it represents a new direction in the treatment of this disease. By completing this trial and demonstrating safety in healthy participants, we are now closer to initiating a Phase 2 trial of Lucid-MS in people with MS."
"We are now looking ahead to our Phase 2 trial as we work towards our goals of drug approval and commercialization of Lucid-MS. We look forward to providing further updates as we execute on our milestones, driven by our mission to arrest demyelination in MS," concluded Saeed.
...
Read the full article here.
-----
#5. QNTM Potential Catalyst - A Multitude Of Bullish Technicals Could Throw A Spotlight On This Nasdaq Biopharma Profile.
On Friday at 4:00PM EST, Barchart was reporting several triggered technical indicators across the short, medium, and long term for QNTM.
Here's their list (as of 4:00PM EST Friday):
Short Term Indicators
- 20 Day Moving Average
- 20 - 100 Day MA Crossover
Medium Term Indicators
- 50 Day Moving Average
- 50 - 100 Day MA Crossover
- 50 - 150 Day MA Crossover
- 50 - 200 Day MA Crossover
Long Term Indicators
- 100 Day Moving Average
- 150 Day Moving Average
- 200 Day Moving Average
The website also shares its all-important "Trend Seeker" composite indicator is triggered as well.
Make sure to watch these technical indicators closely moving forward.
-----
QNTM Recap - 5 Potential Breakout Catalysts To Consider
#1. A Minuscule Float Could Provide Strong Potential For Explosive Volatility.
#2. An Analyst Target Suggests (Nasdaq: QNTM) May Be Undervalued From Current Levels.
#3. Positive Effects Of unbuzzd™ Rapidly Apparent, Occurring Within 30 Min. After Consumption.
#4. Another Milestone Reached As Company Shares Completion Of Key Phase 1 Trial.
#5. A Multitude Of Bullish Technicals Could Throw A Spotlight On This Nasdaq Biopharma Profile.
-----
Coverage is officially reinitiated on (Nasdaq: QNTM). Consider it for your watch-list this week.
Sincerely,
Kai Parker
StockWireNews
